Previous close | 2.0000 |
Open | 1.0000 |
Bid | 0.0000 |
Ask | 3.5000 |
Strike | 1.00 |
Expiry date | 2024-06-21 |
Day's range | 1.0000 - 2.0000 |
Contract range | N/A |
Volume | |
Open interest | 3 |
Significant Reduction in Net Loss and Strategic Clinical Advancements
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024.
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("Common Stock") at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of $2.819 per share of Common Stock issuable upon exercise